Search Results - "Ward, Micheal S"

Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice by Gallo, Linda A., Ward, Micheal S., Fotheringham, Amelia K., Zhuang, Aowen, Borg, Danielle J., Flemming, Nicole B., Harvie, Ben M., Kinneally, Toni L., Yeh, Shang-Ming, McCarthy, Domenica A., Koepsell, Hermann, Vallon, Volker, Pollock, Carol, Panchapakesan, Usha, Forbes, Josephine M.

“…Blood glucose control is the primary strategy to prevent complications in diabetes. At the onset of kidney disease, therapies that inhibit components of the…”
Get full text

Stably engineered nanobubbles and ultrasound - An effective platform for enhanced macromolecular delivery to representative cells of the retina by Thakur, Sachin S, Ward, Micheal S, Popat, Amirali, Flemming, Nicole B, Parat, Marie-Odile, Barnett, Nigel L, Parekh, Harendra S

“…Herein we showcase the potential of ultrasound-responsive nanobubbles in enhancing macromolecular permeation through layers of the retina, ultimately leading…”
Get full text

Tapping into Mitochondria to Find Novel Targets for Diabetes Complications by Flemming, Nicole B, Gallo, Linda A, Ward, Micheal S, Forbes, Josephine M

“…Mitochondria produce the majority of cellular energy via the "slow burn" of substrates such as glucose, free fatty acids and ketones. In diabetes, altered…”
Get more information

Targeting advanced glycation endproducts and mitochondrial dysfunction in cardiovascular disease by Ward, Micheal S, Fotheringham, Amelia K, Cooper, Mark E, Forbes, Josephine M

“…Highlights • Cardiovascular disease (CVD) has many risk factors contributing to development. • Advanced glycation endproducts (AGEs) contribute to many…”
Get full text

Short Duration Alagebrium Chloride Therapy Prediabetes Does Not Inhibit Progression to Autoimmune Diabetes in an Experimental Model by Borg, Danielle J, Faridi, Pouya, Giam, Kai Lin, Reeves, Peta, Fotheringham, Amelia K, McCarthy, Domenica A, Leung, Sherman, Ward, Micheal S, Harcourt, Brooke E, Ayala, Rochelle, Scheijen, Jean L, Briskey, David, Dudek, Nadine L, Schalkwijk, Casper G, Steptoe, Raymond, Purcell, Anthony W, Forbes, Josephine M

“…Mechanisms by which advanced glycation end products (AGEs) contribute to type 1 diabetes (T1D) pathogenesis are poorly understood. Since life-long…”
Get full text

Erratum: Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice by Gallo, Linda A., Ward, Micheal S., Fotheringham, Amelia K., Zhuang, Aowen, Borg, Danielle J., Flemming, Nicole B., Harvie, Ben M., Kinneally, Toni L., Yeh, Shang-Ming, McCarthy, Domenica A., Koepsell, Hermann, Vallon, Volker, Pollock, Carol, Panchapakesan, Usha, Forbes, Josephine M.

“…Scientific Reports 6: Article number: 26428; published online: 26 May 2016; updated: 07 July 2016 This Article contains errors in the Acknowledgements section…”
Get full text

Targeted mitochondrial therapy using MitoQ shows equivalent renoprotection to angiotensin converting enzyme inhibition but no combined synergy in diabetes by Ward, Micheal S., Flemming, Nicole B., Gallo, Linda A., Fotheringham, Amelia K., McCarthy, Domenica A., Zhuang, Aowen, Tang, Peter H., Borg, Danielle J., Shaw, Hannah, Harvie, Benjamin, Briskey, David R., Roberts, Llion A., Plan, Manuel R., Murphy, Michael P., Hodson, Mark P., Forbes, Josephine M.

“…Mitochondrial dysfunction is a pathological mediator of diabetic kidney disease (DKD). Our objective was to test the mitochondrially targeted agent, MitoQ,…”
Get full text

Real-time quantification of oxidative stress and the protective effect of nitroxide antioxidants by Rayner, Cassie L., Bottle, Steven E., Gole, Glen A., Ward, Micheal S., Barnett, Nigel L.

“…Nitroxides have been exploited as profluorescent probes for the detection of oxidative stress. In addition, they deliver potent antioxidant action and…”
Get full text

Deletion of bone-marrow-derived receptor for AGEs (RAGE) improves renal function in an experimental mouse model of diabetes by Tesch, Greg, Sourris, Karly C., Summers, Shaun A., McCarthy, Domenica, Ward, Micheal S., Borg, Danielle J., Gallo, Linda A., Fotheringham, Amelia K., Pettit, Allison R., Yap, Felicia Y. T., Harcourt, Brooke E., Tan, Adeline L. Y., Kausman, Joshua Y., Nikolic-Paterson, David, Kitching, Arthur R., Forbes, Josephine M.

“…Aims/hypothesis The AGEs and the receptor for AGEs (RAGE) are known contributors to diabetic complications. RAGE also has a physiological role in innate and…”
Get full text

The SGLT2 Inhibitor, Empagliflozin, Attenuates Some Markers of Renal Fibrosis without Improving Albuminuria in Diabetic Db/Db Mice by Gallo, Linda A, Ward, Micheal S, Fotheringham, Amelia K, Zhuang, Aowen, Koepsell, Hermann, Vallon, Volker, Pollock, Carol, Panchapakesan, Usha, Forbes, Josephine M

“…Abstract only Sodium‐dependent‐glucose‐transporter 2 (SGLT2) inhibitors are a novel therapy for type 2 diabetes. They block glucose reabsorption by the kidney…”
Get full text